Early-stage Classical Hodgkin Lymphoma (CHL): Can We Eliminate Radiation Therapy for Most Patients?
This information was originally presented at the NCCN 11th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This educational program is designed to meet the educational needs of oncologists, hematologists, nurses, pharmacists, and other healthcare professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Describe the challenges associated with the management of early stage CHL and the need to develop individualized treatment options.
- Review the evidence from recent clinical trials evaluating the use of chemotherapy alone for early stage CHL.
Ranjana H. Advani, MD
Stanford Cancer Institute
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics.
The faculty listed below have disclosed the following relevant financial relationships:
Ranjana H. Advani, MD
Agensys, Inc.: Grant/Research Support
Bristol-Myers Squibb Company: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor
Celgene Corporation: Grant/Research Support
Forty Seven, Inc.: Scientific Advisor
Genentech, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Infinity Pharmaceuticals, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support
Juno Therapeutics: Scientific Advisor
Kura Oncology, Inc.: Grant/Research Support
Kyowa Hakko Kirin Co, Ltd.: Scientific Advisor
Merck & Co., Inc.: Grant/Research Support
Millennium Pharmaceuticals, Inc.: Grant/Research Support
NanoString® Technologies, Inc.: Consulting Fees, Honoraria
Pharmacyclics: Consulting Fees, Honoraria; Grant/Research Support
Regeneron Pharmaceuticals, Inc.: Grant/Research Support
Roche Laboratories, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Seattle Genetics, Inc.: Grant/Research Support
Spectrum Pharmaceuticals, Inc.: Consulting Fees, Honoraria; Scientific Advisor
Sutro Biopharma, Inc.: Scientific Advisor
NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:
Robert W. Carlson, MD; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser
The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Jennifer Burns; Hema Sundar, PhD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
National Comprehensive Cancer Network designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim onlhy the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.50 hours of Category I credit for completing this program.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.44 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
|National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Type of Activity: Knowledge
National Comprehensive Cancer Network designates this continuing education activity for 0.50 contact hours (0.050 CEUs) of continuing education credit in states that recognize ACPE accredited providers.
Universal Activity Number: 0836-0000-16-094-H01-P
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.44 ANCC contact hours
- 0.50 Participation